Braskem (BRKM5) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 Jul, 2026Executive summary
Recurring EBITDA reached US$192 million in Q1 2026, up 76% from Q4 2025, driven by higher spreads, positive tax credits in Brazil, and improved performance in the US and Europe, despite a negative result in Mexico.
Net income attributable to shareholders was US$275 million, reversing a loss in the previous quarter, mainly due to positive exchange rate effects and tax asset write-offs.
Operating cash consumption was US$603 million (R$3.2 billion), mainly due to negative working capital changes, inventory replenishment, and semiannual debt interest payments.
Cash position ended at US$1.1 billion, including a $1 billion standby facility, but decreased 46% sequentially.
Material uncertainty exists regarding going concern due to negative equity, high leverage, and Braskem Idesa's financial distress.
Financial highlights
Net revenue was US$2.95 billion (R$15,488 million), down 1% sequentially and 12% year-over-year.
Recurring EBITDA margin improved to 7% in Q1 2026, up from 4% in Q4 2025.
Adjusted net debt was US$8.5 billion, with leverage at 16.81x and gross debt at US$12.05 billion.
Net profit attributable to shareholders was R$1,446 million, up from R$698 million year-over-year, driven by positive financial results from derivatives and exchange rate variations.
Cash and cash equivalents decreased to R$4,678 million from R$10,501 million at year-end.
Outlook and guidance
Priorities for 2026 include capital structure reorganization, liquidity preservation, competitiveness initiatives, and sustainability expansion.
External consultancies expect material improvement in petrochemical spreads in Q2 2026, normalizing from Q3 as supply stabilizes.
Projections assume the Middle East conflict ends in May; prolonged conflict could further impact spreads and demand.
Management expects continued pressure on liquidity due to industry downturn, high debt service, and obligations from the Alagoas geological event.
Complementary Law No. 228 increased REIQ benefit for the chemical industry, providing significant tax credits through December 2026.
Latest events from Braskem
- EBITDA surged 121% to US$224M, but Alagoas-related risks remain significant.BRKM5
Q1 20259 Jul 2026 - EBITDA surged 104% sequentially, but net loss and high leverage persisted amid legal and market headwinds.BRKM5
Q3 20259 Jul 2026 - EBITDA surged 39–46%, but net loss widened on currency impacts; liquidity remains strong.BRKM5
Q2 20248 Jul 2026 - Recurring EBITDA fell 49% and net loss reached R$10,961m amid high leverage and industry downturn.BRKM5
Q4 20258 Jul 2026 - EBITDA plunged 67%, leverage hit 10.59x, and legal, market, and cash flow risks remain.BRKM5
Q2 20257 Jul 2026 - EBITDA up 46% to US$1.1B, but FX losses led to a net loss; strong liquidity and green focus.BRKM5
Q4 20243 Jul 2026 - EBITDA hit a two-year high on margin gains, but legal and currency risks remain.BRKM5
Q3 20243 Jul 2026 - 2030 targets: 1M tons each of bio-based and recycled products, with ambitious decarbonization goals.BRKM5
Investor Day 202412 Jan 2026